Merck Signs an Exclusive Agreement with Dewpoint Therapeutics to Develop Curative Treatment for HIV

 Merck Signs an Exclusive Agreement with Dewpoint Therapeutics to Develop Curative Treatment for HIV

Merck Signs an Exclusive Agreement with Dewpoint Therapeutics to Develop Curative Treatment for HIV

Shots:

  • Dewpoint to receive up to $305M as up front and milestone along with royalties on sales of any approved product emerges under the collaboration
  • The collaboration leverages Dewpoint’s biomolecular condensate platform to develop an HIV drug candidate with a unique mechanism, providing the potential to cure rather than suppressing the infection
  • Biomolecular condensates are droplet-like structures that form dynamically within cells when diverse communities of proteins, RNAs, and other biomolecules come together through a process called phase separation

Click here to read full press release/ article | Ref: Dewpoint | Image: Biospace

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post